Clinical Trials Logo

Thyroid Carcinoma, Anaplastic clinical trials

View clinical trials related to Thyroid Carcinoma, Anaplastic.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06235216 Not yet recruiting - Clinical trials for Differentiated Thyroid Cancer

Sacituzumab govitEcan in THYroid Cancers

SETHY
Start date: February 2024
Phase: Phase 2
Study type: Interventional

SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated thyroid carcinoma (DTC) or anaplastic thyroid carcinoma (ATC). The main hypothesis is that treatment with sacituzumab govitecan, a anti-Trophoblast cell surface antigen 2 (TROP-2), could be an effective treatment option for patients with either differentiated and anaplastic thyroid neoplasms because TROP-2 is highly expressed at the membrane of DTC and ATC.

NCT ID: NCT05819593 Not yet recruiting - Clinical trials for Anaplastic Thyroid Cancer

Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences

Start date: May 2024
Phase:
Study type: Observational

Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative. The goal is to identify the obstacles and challenges that prevent participation in anaplastic thyroid cancer clinical research, as well as the reasons for withdrawal or discontinuation. Insights gained from this study will ultimately benefit those with anaplastic thyroid cancer who may be invited to participate in clinical research in the years to come.

NCT ID: NCT04574817 Not yet recruiting - Clinical trials for Anaplastic Thyroid Cancer

Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)

Start date: December 28, 2020
Phase: Phase 2
Study type: Interventional

There are currently no target therapies approved for treatment of anaplastic thyroid cancer (ATC), leading to a clear need for improving therapy for ATC. This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008 injection in patients with metastatic or locally advanced anaplastic thyroid cancer.